Coronary stent evolution with novel metal alloy composition, reduced strut thickness, enhanced platform flexibility and conformability, and improved polymer biocompatibility and/or bioresorption has been associated with progressive, step-wise reductions in major adverse cardiovascular events (MACE), including stent thrombosis (ST), compared with bare-metal stents (BMSs) as well as first-generation and newer-generation drug-eluting stents (DESs).1 The greatest differential in device-related events between these disparate platforms is in the first year following deployment; beyond 1 year, there is a 2% to 4% annual incidence of events regardless of device. Although BMSs have significantly higher rates of angiographic and clinical restenosis, their use is advocated for patients, “with a large vessel diameter in whom restenosis rates are low, those who cannot complete the longer duration of dual-antiplatelet therapy recommended for drug-eluting stents because of noncompliance or need for noncardiac surgery, those who cannot pay for drug-eluting stents or a longer duration of dual-antiplatelet therapy because of increased cost, and those at increased risk for bleeding.”2